EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024)

Hassan Aliashrafzadeh, Dewey Liu, Samantha De Alba, Imad Akbar, Austin Lui, Jordan Vanleuven, Ryan Martin, Zhang Wang iD, Da Zhi Liu iD

Exploration of Drug Science · 01.07.2025 · 3

DOI: 10.37349/eds.2025.1008116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Drug Science, online erschienen am 01.07.2025. Verfasst von Hassan Aliashrafzadeh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of California, Davis, CA 95616, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 626 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since our previous summary of the 74 FDA-approved kinase inhibitors in clinical and preclinical trials for non-cancerous neurological treatment, the US FDA has approved 13 additional kinase inhibitors since early 2022. This update incorporates new evidence for the now 87 FDA-approved kinase inhibitors in clinical and preclinical trials for the treatment of non-cancerous neurological disorders. By the end of October 2024, nearly all 87 FDA-approved kinase inhibitors have been tested in various animal models of non-cancerous neurological disorders, with twenty entered into clinical trials and six used for off-label treatments of neurological conditions in humans. Considering the challenges posed by intellectual property (IP), legal considerations, and limited blood-brain barrier (BBB) permeability, which may restrict some FDA-approved kinase inhibitors from effectively targeting the central nervous system (CNS), we further discuss the feasibility of designing novel proprietary analogs with enhanced BBB penetration to improve their therapeutic potential in neurological disorders. The new drugs typically retain full IP rights and remain costly; while repurposing kinase inhibitors may provide effective and affordable treatments for non-cancerous neurological disorders.

Schlagwörter

Stichwörter der Autor:innen

Kinase inhibitorsaberrant cell cycleclinical trialsneurological disorderspreclinical experiments

Autor:innen und Institutionen

  • Department of Neurology, University of California, Davis, CA 95616, USA.
  • Ayub Medical College, Abbottabad 22020, Pakistan.
  • Department of Neurological Surgery, University of California, Davis, CA 95616, USA.
  • Institute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616, USA.
  • Department of Chemistry, University of California, Davis, CA 95616, USA.
  • Mirnova Therapeutics, Inc., Davis, CA 95618, USA.

ORCID-Profile: Zhang Wang, Da Zhi Liu

Förderung

  • NINDS NIH HHS

Zitieren

APA

Aliashrafzadeh, H., Liu, D., De Alba, S., Akbar, I., Lui, A., Vanleuven, J., Martin, R., Wang, Z., & Liu, D. Z. (2025). Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024). Exploration of Drug Science, 3. https://doi.org/10.37349/eds.2025.1008116

Vancouver

Aliashrafzadeh H, Liu D, De Alba S, Akbar I, Lui A, Vanleuven J, et al. Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024). Exploration of Drug Science. 2025;3. doi:10.37349/eds.2025.1008116

BibTeX
@article{Aliashrafzadeh2025,
  author = {Aliashrafzadeh, Hassan and Liu, Dewey and De Alba, Samantha and Akbar, Imad and Lui, Austin and Vanleuven, Jordan and Martin, Ryan and Wang, Zhang and Liu, Da Zhi},
  title = {Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024)},
  journal = {Exploration of Drug Science},
  year = {2025},
  volume = {3},
  doi = {10.37349/eds.2025.1008116}
}
Kostenlos starten →